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PRESS STATEMENT BY THE MINISTER FOR HEALTH, PR D.N. EVERINGHAM 
WARNING ON 'TRAVELLER'S DIARRHOEA' MEDICINES 
The Minister for Health, Dr D.N. Everingham, said today-
he was most concerned about the continued availability in some States 
of certain medicines without prescription. 
The medicines, sold mainly for the prevention of 
'traveller's diarrhoea', contain substances called halogenated 
hydroxyquinolines. 
They are sold in Australia under various names, including 
Budoform, Clioquinol, Diodoquin, Direxiode, Embequin, Enteroquin, 
Enterovioform, Eviform, Intestopan, Mexaform and Oletron. 
Dr Everingham said that both the Australian Drug Evaluation 
Committee and the National Health and Medical Research Council had 
recommended that these preparations be available only on prescription. 
But the recommendation had not yet been adopted by all 
States, and in New South Vales, Victoria, South Australia and Tasmania 
the medicines were still being sold as over-the-counter items 
(although adoption of this recommendation in South Australia is 
imminent, discussion is taking place in Tasmania.) 
Dr Everingham said there was no conclusive evidence that 
the medicines were effective for preventing traveller's diarrhoea. 
But there was a substantial body of scientific evidence 
both at home and overseas that prolonged use of certain medicines 
in this group could cause., in some instances, a slow, progressive 
and sometimes irreversible loss of vision and loss of normal sensatior 
in the feet and legs - a medical condition known as sub-acute 
myelo-optic neuropathy, or SMON. 
Dr Everingham said 19 Australian cases consistent with a 
diagnosis of SMON and associated with high doses of, or prolonged 
therapy with, halogenated hydroxyquinolines had been reported to the 
Drug Evaluation Committee. In addition reports of other Australian 
cases have been published in professional journals. 
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A cautionary statement had previously been made by the 
Drug Evaluation Committee in November 1971, and recently the 
Committee had written to all Australian medical practitioners 
alerting them to these facts, urging them to take care in prescribing 
such preparations, and recommending that they urge their patients 
to avoid using them while travelling. A copy of the letter has 
also been circulated to family chemists. 
Dr Everingham said he was anxious that people in those 
States where the medicines were available without prescription 
should also be alerted to the potential danger. 
He drew attention to the advice of informed medical opinion 
that these preparations should not be used routinely by travellers, 
and never for four weeks or more without medical advice. 
Dr Everingham added that he hoped it would not be long 
before all States legislated to make the medicines available only 
on prescription. 
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